Dr. Hoos on Tools Available to Measure Ipilimumab's Success

Dr. Axel Hoos from Bristol Myers-Squibb on Tools Available to Measure Ipilimumab's Success

Axel Hoos, MD, PhD, the medical lead in Immunology/Oncology at Bristol-Myers Squibb describes the tools currently available and peer reviewed for the measurement of ipilimumab's success. These studies all need to be validated prospectively in comparison to standard processes.